{"nctId":"NCT01275365","briefTitle":"Optimizing Protein Intake in Older Americans With Mobility Limitations","startDateStruct":{"date":"2011-05"},"conditions":["Mobility Limitation"],"count":92,"armGroups":[{"label":"Placebo/Low Protein","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Placebo/High Protein","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Testosterone/Low Protein","type":"OTHER","interventionNames":["Drug: Testosterone enanthate"]},{"label":"Testosterone/High Protein","type":"OTHER","interventionNames":["Drug: Testosterone enanthate"]}],"interventions":[{"name":"Testosterone enanthate","otherNames":[]},{"name":"Testosterone enanthate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Community-dwelling men 65 years of age or older\n2. A score of 3-10 on the short physical performance battery (SPPB)\n3. Daily protein intake less than the recommended daily allowance of 0.83 g/kg/day (from 3 24-hour food recalls)\n4. Able to give informed consent\n\nExclusion Criteria:\n\n1. History of prostate or breast cancer\n2. American Urological Association \\[AUA\\] symptom index score of \\>19\n3. Prostate specific antigen (PSA) \\>4 ng/ml in White men or \\>3 ng/ml in Black men\n4. Prostate specific antigen (PSA) \\> 4 ng/ml in non-Black men or \\>3 ng/ml in Black men. These subjects may be enrolled if they have a negative transrectal biopsy within the past year.\n5. Myocardial infarction or stroke within the last 6 months\n6. Uncontrolled congestive heart failure, based on the study physician's evaluation\n7. Serum creatinine \\> 2.0 mg/dL; men on any kind of dialysis will be excluded.\n8. History of celiac disease, Crohn's disease, or ulcerative colitis\n9. History of any malignancy requiring treatment within the previous 2 years, except non-melanic skin cancers. Men with cancers who have not required active treatment within the past two years and who have not had disease recurrence within the past two years may be enrolled at the discretion of the study physician.\n10. Neuromuscular diseases: motor neuron diseases, multiple sclerosis, adult muscular dystrophies, and myasthenia gravis\n11. History of stroke with residual limb weakness that affected the individual's ability to walk; subjects with history of stroke who do not have residual limb weakness may be enrolled.\n12. Schizophrenia, bipolar disorder, or untreated diagnosed depression. Subjects with unipolar depression who are on an antidepressant medication are eligible.\n13. TSH levels \\<0.4 or \\>5 mlU/L\n14. Systolic blood pressure (BP) \\>160 or diastolic BP \\>100 mm Hg (average of 2 measurements taken at Visit 1)\n15. Hemoglobin A1c \\>8.0% or taking insulin. Men with diabetes mellitus whose A1C is less than 8.0% or who are not taking insulin will be eligible.\n16. Mini-Mental Status Exam \\[MMSE\\] \\<24\n17. Body mass index (BMI) less than 20 or greater than 40 kg/m2\n18. Not willing to eat all of the following: red meat, eggs, poultry, fish and shellfish\n19. Allergy to sesame, peanuts, soy, gluten or shellfish\n20. Current alcohol use \\>21 drinks/week based on self-report\n21. Confinement to a wheelchair\n22. Use of anabolic therapies (Testosterone, DHEA, androstenedione, rhGH) within the past year\n23. Current use of levodopa or anticoagulants\n24. Current enrollment in a structured weight management program or participation in any weight intervention studies in the last 90 days\n25. Serum ALT and AST greater than 3 x upper limit of normal\n26. Hematocrit \\< 30% or \\>48%\n27. Subject is not able to eat 3 frozen study meals per day for 6 months\n28. Subject is unwilling to stop current nutritional supplements\n29. Progressive intensive resistance training within 12 weeks of screening\n30. Non-compliant with run-in diet and/or supplement","healthyVolunteers":false,"sex":"MALE","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA)","description":"Primary outcome is change in lean body mass, measured by dual energy X-ray absorptiometry (DXA)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.31"},{"groupId":"OG001","value":"0.74","spread":"0.33"},{"groupId":"OG002","value":"4.43","spread":"0.48"},{"groupId":"OG003","value":"4.13","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Change of Maximal Voluntary Strength","description":"Tests of Muscle Performance: (1) Maximal voluntary strength measured by 1-repetition maximum method in leg press; (2) Maximal voluntary strength in chest press; this exercise was chosen because it involves the large muscle groups of the upper extremities.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.6","spread":"46.4"},{"groupId":"OG001","value":"156.0","spread":"89.1"},{"groupId":"OG002","value":"201.8","spread":"44.4"},{"groupId":"OG003","value":"191.4","spread":"38.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","spread":"12.3"},{"groupId":"OG001","value":"16.6","spread":"9.2"},{"groupId":"OG002","value":"64.5","spread":"11.9"},{"groupId":"OG003","value":"59.3","spread":"11.3"}]}]}]},{"type":"SECONDARY","title":"Change of Leg Press Power","description":"Muscle Performance measured using Power of hip and knee extension by Bassey's leg rig.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":"17.0"},{"groupId":"OG001","value":"96.9","spread":"19.6"},{"groupId":"OG002","value":"61.5","spread":"22.2"},{"groupId":"OG003","value":"81.7","spread":"16.1"}]}]}]},{"type":"SECONDARY","title":"Change of 6-minute Walking Distance","description":"Tests of Physical Function and Task-Specific Performance measured by 6-min walking distance","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":"17.9"},{"groupId":"OG001","value":"49.9","spread":"14.2"},{"groupId":"OG002","value":"38.2","spread":"21.9"},{"groupId":"OG003","value":"25.5","spread":"11.5"}]}]}]},{"type":"SECONDARY","title":"Change of Stair Climbing Tests","description":"Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry. Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: \\[body weight (kilograms) \\* distance (meters)/ (time/60)\\] /6.12.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":"19.2"},{"groupId":"OG001","value":"55.4","spread":"14.2"},{"groupId":"OG002","value":"53.2","spread":"17.5"},{"groupId":"OG003","value":"4.2","spread":"13.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":"15.7"},{"groupId":"OG001","value":"83.7","spread":"28.5"},{"groupId":"OG002","value":"56.6","spread":"18.8"},{"groupId":"OG003","value":"26.9","spread":"14.3"}]}]}]},{"type":"SECONDARY","title":"Change of 50-meter Loaded Walking Test","description":"Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry. Physical Function was evaluated using test of 50-meter loaded walking speed. The test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags. Time was measured electronically with a digital clock. Speed in meters per second is calculated by the following: 50/time.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.04"},{"groupId":"OG001","value":"0.11","spread":"0.05"},{"groupId":"OG002","value":"0.06","spread":"0.05"},{"groupId":"OG003","value":"0.08","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change of Self-reported Physical Function Domain of Short Form Health Survey (SF-36)","description":"36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Physical function domain of the Medical Outcomes Study Short Form-36 (SF-36) contains 10 items with the score range of 0-100. Higher score yields better performance.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"3.1"},{"groupId":"OG001","value":"-5.5","spread":"5.3"},{"groupId":"OG002","value":"2.1","spread":"2.8"},{"groupId":"OG003","value":"-2.9","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change of Psychological Well Being Index (PGWBI)","description":"The PGWBI is a 22-item health-related Quality of Life (HRQoL) questionnaire developed in US which produces a self-perceived evaluation of psychological well-being expressed by a summary score. The 22 items are grouped in 6 dimensions. A global score is computed as the sum of all items with range of 0-110. A higher score yields better performance.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"1.53"},{"groupId":"OG001","value":"1.17","spread":"1.77"},{"groupId":"OG002","value":"0.32","spread":"2.08"},{"groupId":"OG003","value":"2.68","spread":"1.58"}]}]}]},{"type":"SECONDARY","title":"Change of Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale","description":"The FACIT Fatigue Scale is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"1.56"},{"groupId":"OG001","value":"-0.14","spread":"1.41"},{"groupId":"OG002","value":"-0.53","spread":"1.39"},{"groupId":"OG003","value":"1.05","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Change of Derogatis Affective Balance Scale (DABS)","description":"The Derogatis Affects Balance Scale (DABS) is a multidimensional self-report mood and affects inventory comprised of 40 adjective-items using a 5-point Likert style scale. The DABS global scores consist of the Positive Total score (PTOT), Negative Total score (NTOT), where The Positive Affects Total (PTOT) is defined as the sum of all scores on the four positive affects dimensions of joy, contentment, vigor and affection, ranging 0-80. Similarly, the Negative Affects Total (NTOT) is represented as the sum of scores on the four negative dimensions of anxiety, depression, guilt and hostility, ranging 0-80. The Affects Expressiveness Index (AEI) is defined as the sum total of PTOT and NTOT, ranging 0-160. Higher score yields stronger affective intensity.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"3.54"},{"groupId":"OG001","value":"1.45","spread":"1.96"},{"groupId":"OG002","value":"-0.50","spread":"2.51"},{"groupId":"OG003","value":"-3.17","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"2.09"},{"groupId":"OG001","value":"2.10","spread":"1.70"},{"groupId":"OG002","value":"0.69","spread":"1.68"},{"groupId":"OG003","value":"1.89","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"2.03"},{"groupId":"OG001","value":"-0.65","spread":"1.36"},{"groupId":"OG002","value":"-0.88","spread":"2.85"},{"groupId":"OG003","value":"-5.53","spread":"1.47"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":24},"commonTop":["Back pain","Upper respiratory tract infection","Prostatic specific antigen abnormal","Arthralgia","Muscle strain"]}}}